Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Paul J. Richards/AFP/Getty Images
The Federal Trade Commission plans to hold antitrust hearings later this year, and health care groups haven't been shy about telling regulators this month what they want done with the pharmaceutical industry.
Between the lines: The Hatfields and the McCoys still have guns pointed toward each other.
What they're saying:
- Consumer groups teamed up with America's Health Insurance Plans to urge the FTC to "stop sham and anticompetitive transactions that unnecessarily delay generic drug and biosimilar competition."
- Former Rep. Henry Waxman told the FTC it should conduct a deep analysis of pharmacy benefit manager consolidation and how PBM contracts affect drug prices.
- PhRMA, building on its long campaign against PBMs, similarly wants pharmacy benefit rebates to be scrutinized.